NIKKEI 225
37,151.97 -927.73 (-2.44%) HANG SENG
16,184.02 -201.85 (-1.23%) CRUDE OIL
84.83 +2.10 (+2.54%) GOLD FUTURES
2,403.10 +5.10 (+0.21%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,138.69 +374.14 (+0.75%)
AstraZeneca PLC (ZEG.MU)
| Previous close | 127.60 |
| Open | 128.85 |
| Bid | 127.85 x 0 |
| Ask | 128.45 x 0 |
| Day's range | 128.85 - 128.85 |
| 52-week range | 113.00 - 138.30 |
| Volume | |
| Avg. volume | 41 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Fool.co.ukI don’t care how much FTSE bosses are paid as long as they make me rich!
Facing accusations of greed, the pay packages of FTSE CEOs are back in the headlines. But our writer takes a more relaxed view, on one condition. The post I don’t care how much FTSE bosses are paid as long as they make me rich! appeared first on The Motley Fool UK.
Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
Business WireFASENRA approved for treatment of children aged 6 to 11 with severe asthma
WILMINGTON, Del., April 11, 2024--AstraZeneca’s FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1
